Brown Rudnick Advises RA Capital on IP Matters in Artios Pharma's $115 Million Series D Financing

"Brown Rudnick advised RA Capital Management on intellectual property matters related to Artios Pharma Limited’s $115 million Series D financing, which closed on November 17, 2025. RA Capital co-led the round with SV Health Investors, joined by Janus Henderson and existing shareholders. Proceeds will advance Artios’ clinical programs including alnodesertib and ART6043."

Brown Rudnick advised RA Capital Management on intellectual property matters in connection with Artios Pharma Limited’s $115 million Series D financing. The financing, which closed on November 17, 2025, was co-led by RA Capital Management and founding investor SV Health Investors, and was joined by new investor Janus Henderson Investors with strong participation from existing shareholders. Proceeds will enable Artios to advance its clinical pipeline, including expanded development of its lead program, alnodesertib, in ATM-negative second-line pancreatic cancer and third-line colorectal cancer. The funds will also support a Phase 2 randomized clinical trial of ART6043, Artios’ second first-in-class candidate, in BRCA-mutant, HER2-negative breast cancer. Brown Rudnick represented RA Capital Management with a team composed by: partner Adam Schoen (intellectual property) and senior patent agent Hugo Garrido (intellectual property).

Brown Rudnick Advises RA Capital on IP Matters in Artios Pharma's $115 Million Series D Financing

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads